118 related articles for article (PubMed ID: 22244201)
1. Biodistribution and Tumor Localization of PEG-Modified Dendritic Poly(L-Lysine) Oligonucleotide Complexes.
Kurihara R; Pissuwan D; Mori T; Katayama Y; Niidome T
J Biomater Sci Polym Ed; 2012; 23(18):2369-80. PubMed ID: 22244201
[TBL] [Abstract][Full Text] [Related]
2. Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine).
Niidome T; Yamauchi H; Takahashi K; Naoyama K; Watanabe K; Mori T; Katayama Y
J Biomater Sci Polym Ed; 2014; 25(13):1362-73. PubMed ID: 25040893
[TBL] [Abstract][Full Text] [Related]
3. Grafting of poly(ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA.
Kano A; Moriyama K; Yamano T; Nakamura I; Shimada N; Maruyama A
J Control Release; 2011 Jan; 149(1):2-7. PubMed ID: 20005270
[TBL] [Abstract][Full Text] [Related]
4. Partly-PEGylated Poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers.
Kaminskas LM; Wu Z; Barlow N; Krippner GY; Boyd BJ; Porter CJ
J Pharm Sci; 2009 Oct; 98(10):3871-5. PubMed ID: 19283758
[TBL] [Abstract][Full Text] [Related]
5. Nitroxyl radicals-modified dendritic poly(l-lysine) as a contrast agent for Overhauser-enhanced MRI.
Niidome T; Gokuden R; Watanabe K; Mori T; Naganuma T; Utsumi H; Ichikawa K; Katayama Y
J Biomater Sci Polym Ed; 2014; 25(13):1425-39. PubMed ID: 25088777
[TBL] [Abstract][Full Text] [Related]
6. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms.
Clementi C; Miller K; Mero A; Satchi-Fainaro R; Pasut G
Mol Pharm; 2011 Aug; 8(4):1063-72. PubMed ID: 21608527
[TBL] [Abstract][Full Text] [Related]
7. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.
Kaminskas LM; Kota J; McLeod VM; Kelly BD; Karellas P; Porter CJ
J Control Release; 2009 Dec; 140(2):108-16. PubMed ID: 19686787
[TBL] [Abstract][Full Text] [Related]
8. Lactose-poly(ethylene glycol)-grafted poly-L-lysine as hepatoma cell-tapgeted gene carrier.
Choi YH; Liu F; Park JS; Kim SW
Bioconjug Chem; 1998; 9(6):708-18. PubMed ID: 9815164
[TBL] [Abstract][Full Text] [Related]
9. Study on galactose-poly(ethylene glycol)-poly(L-lysine) as novel gene vector for targeting hepatocytes in vitro.
Hu HM; Zhang X; Zhong NQ; Pan SR
J Biomater Sci Polym Ed; 2012; 23(5):677-95. PubMed ID: 21375808
[TBL] [Abstract][Full Text] [Related]
10. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers.
Kojima C; Regino C; Umeda Y; Kobayashi H; Kono K
Int J Pharm; 2010 Jan; 383(1-2):293-6. PubMed ID: 19761822
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer.
Fu F; Wu Y; Zhu J; Wen S; Shen M; Shi X
ACS Appl Mater Interfaces; 2014 Sep; 6(18):16416-25. PubMed ID: 25185074
[TBL] [Abstract][Full Text] [Related]
12. Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer.
Li J; Jiang X; Guo Y; An S; Kuang Y; Ma H; He X; Jiang C
Bioconjug Chem; 2015 Mar; 26(3):418-26. PubMed ID: 25675244
[TBL] [Abstract][Full Text] [Related]
13. Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly(ethylene glycol)-block-poly(L-lysine): a potential carrier for systemic delivery of antisense DNA.
Kakizawa Y; Harada A; Kataoka K
Biomacromolecules; 2001; 2(2):491-7. PubMed ID: 11749211
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of poly(ethylene glycol) derivatives as diagnostic drug carriers for tumor imaging.
Kanazaki K; Sano K; Makino A; Yamauchi F; Takahashi A; Homma T; Ono M; Saji H
J Control Release; 2016 Mar; 226():115-23. PubMed ID: 26869546
[TBL] [Abstract][Full Text] [Related]
15. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice.
Okuda T; Kawakami S; Akimoto N; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Dec; 116(3):330-6. PubMed ID: 17118476
[TBL] [Abstract][Full Text] [Related]
16. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice.
Singh P; Gupta U; Asthana A; Jain NK
Bioconjug Chem; 2008 Nov; 19(11):2239-52. PubMed ID: 18950215
[TBL] [Abstract][Full Text] [Related]
17. Precise engineering of siRNA delivery vehicles to tumors using polyion complexes and gold nanoparticles.
Kim HJ; Takemoto H; Yi Y; Zheng M; Maeda Y; Chaya H; Hayashi K; Mi P; Pittella F; Christie RJ; Toh K; Matsumoto Y; Nishiyama N; Miyata K; Kataoka K
ACS Nano; 2014 Sep; 8(9):8979-91. PubMed ID: 25133608
[TBL] [Abstract][Full Text] [Related]
18. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) micelles for rapamycin delivery: in vitro characterization and biodistribution.
Lu W; Li F; Mahato RI
J Pharm Sci; 2011 Jun; 100(6):2418-29. PubMed ID: 21264854
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration.
Okuda T; Kawakami S; Maeie T; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Aug; 114(1):69-77. PubMed ID: 16814896
[TBL] [Abstract][Full Text] [Related]
20. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
